Bio-Techne Corporation

Signal Note: Deerfield Exit from Bio-Techne (TECH)

Deerfield Management's full exit of ~21k shares (-$1.2M) from TECH warrants attention given the firm's selective healthcare focus, though the modest position size limits conviction weight. TECH is a life sciences tools company (flow cytometry, protein analysis), not a clinical-stage biotech, so this likely reflects portfolio rebalancing or valuation concerns rather than pipeline risk. Cross-check whether other specialist healthcare funds have similarly reduced exposure to identify broader sentiment shift on the tools sector or TECH's specific guidance.